- Blocks postsynaptic mesolimbic dopaminergic δ1 (Delta 1) and δ2 (Delta 2) receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones; believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis sites.
- Onset of action:
- Sedation: IM, IV: 30 to 60 minutes
- Emergency sedation of severely agitated or delirious patients.
- Hypersensitivity to haloperidol or any component of the formulation.
- Parkinson's disease.
- Severe CNS depression; coma.
- Increased mortality in geriatric patients with dementia-related psychosis.
- Increased risk of death with use of either conventional (first-generation) or atypical (second-generation) antipsychotics in geriatric patients with dementia-related psychosis.
- Use of higher than recommended doses of any haloperidol formulation and IV administration of the drug appear to be associated with an increased risk of QT-interval prolongation and torsades de pointes.
- Extrapyramidal reactions (e.g., Parkinson-like symptoms, akathisia, dystonia).
- Be aware that dystonic reactions occur more frequently with IV use.
- If dystonic reactions occur treat with 25-50mg of IV Benadryl.
- 5 - 10 mg IM
- 2 - 5 mg IV incrementally to effect
Safety and efficacy not established in children.